PFE — Pfizer, Inc. Common Stock
Session close: $27.54. Regular-session share volume: 29,615,254. Change from previous close: -1.85%.
Key developments
Pfizer signed a licensing deal with Chinese biotech Starna worth billions, adding three investigational CAR-T programs and strengthening its push into next-generation autoimmune treatments. Separate coverage said new launches and acquisitions are reshaping the business and supporting ambitions to return to growth later in the decade.
Company news PFE Inks $2.6B Licensing Deal With Chinese Biotech for CAR-T Therapies · Company news Can New Products and Acquisitions Revive Pfizer's Growth Story?
Pfizer detailed at a customer event how AI workflows cut its insight-to-action cycle from roughly a year to under two weeks, speeding production-ready changes. Context coverage flagged weaker profit margins than a year earlier and a dividend not well covered by earnings as company-specific pressures.
Company news Pfizer Accelerates Insight-to-Action Cycle Using AI Workflows · Company news 3 ETFs That Give You Pfizer With Very Different Mixes
News sources
Company news PFE Inks $2.6B Licensing Deal With Chinese Biotech for CAR-T Therapies · Company news 3 ETFs That Give You Pfizer With Very Different Mixes · Company news Can New Products and Acquisitions Revive Pfizer's Growth Story? · Company news Pfizer Accelerates Insight-to-Action Cycle Using AI Workflows